Weight loss drugs 'linked to hair loss'

Weight loss drugs 'linked to hair loss' - study

Your browser does not support Javascript. Please turn Javascript on to get the best experience from rte.ie

Weather

Discover Discover

RTÉ Games

RTÉ Archives

RTÉ Brainstorm

History

Gaeilge

RTÉ Learn

Food

RTÉ Food

RTÉ Recipes

Watch Watch

RTÉ Player

RTÉ One

RTÉ2

RTÉ News

RTÉjr

Listen Listen

Radio

Podcasts

RTÉ Radio 1

RTÉ 2FM

RTÉ lyric fm

RTÉ Raidió na Gaeltachta

Services Services

Orchestra

RTÉ Weather

Century Ireland

Kids Kids

RTÉ Kids

RTÉ Learn

Help Help

Contact

Feedback

Accessibility

Complaints

Terms & Conditions

Individual Rights Guide

Cookie Policy

Freedom of Information

Helplines

Information Information

About RTÉ

TV Licence

Vacancies

Latest Annual Report

Advertise with RTÉ

2rn

Saorview

Newsletters

RTÉ Supporting the Arts

Policies and Reports

See all results

Updated / Thursday, 23 Jul 2026 07:07

Getty

Experts used electronic patient data from the University of Pennsylvania Health System.

Weight loss and diabetes drugs like Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.

People on GLP-1 agonist drugs have been reporting hair loss to regulators, but a new study on around 50,000 people appears to firm up the link.

Experts used electronic patient data from the University of Pennsylvania Health System to compare rates of alopecia hair loss in adults using GLP-1s to manage diabetes with those on other drugs.

The team noted that regulators in the US have been informed of the link between the drugs and hair loss, particularly for semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro).

So far in 2026, the UK Medicines and Healthcare products Regulatory Agency has received 399 reports of hair loss relating to tirzepatide, alongside 541 last year.

It has also received 148 reports of hair loss linked to semaglutide, alongside 164 reports last year.

For the new study, the team looked at people with type 2 diabetes on GLP-1 receptor agonists or other types of diabetes drugs known as SGLT-2 inhibitors, or DPP-4 inhibitors.

In total, 12,004 patients using GLP-1s were compared with 15,221 using SGLT-2 inhibitors and a further 11,964 GLP-1 users were compared with 11,233 DPP-4 inhibitor users.

After adjusting for factors that could influence the results, such as age and weight, researchers found using GLP-1 drugs were associated with a 37% higher risk of alopecia than use of SGLT-2 inhibitors.

GLP-1s were also linked to a 68% higher risk of hair loss than use of DPP-4 inhibitors.

Further analysis suggested the link related to non-scarring alopecia (where hair follicles remain intact, leaving the potential for hair to regrow).

The researchers, including from the University of Pennsylvania in the US, wrote in the British Medical Journal: "Case reports and analyses of the US Food and Drug Administration's Adverse Event Reporting System have described occurrences of hair loss following initiation of a GLP-1 receptor agonist, particularly semaglutide and tirzepatide.

"In response, the FDA has indicated that it is evaluating this potential safety signal.

"Although hair loss does not typically result in physical harm, it may have significant psychosocial consequences, affecting self-esteem, quality of life, and adherence to treatment."

On the reasons why people may suffer hair loss while on the drugs, the team said the "most likely mechanism" relates to weight loss and "reduced caloric intake", though more research is needed.

They said restricting calories may "contribute to physiological stress and micronutrient deficiencies (for example, iron, zinc, biotin), which can disrupt the hair growth cycle".

Other factors may include the "metabolic, hormonal, and immunological effects attributed to GLP-1 receptor agonists that may influence hair follicle growth and cycling".

For example, GLP-1 receptor agonists have been associated with changes in thyroid function and delayed gastric emptying may alter the absorption of orally administered drugs, including thyroid hormone or sex hormone therapies, they said.

"Such changes could influence hair growth through endocrine mechanisms, particularly in individuals with underlying hormonal conditions."

The team concluded: "Our findings extend previous anecdotal safety signals and provide more systematic evidence to inform clinical awareness of this potential adverse effect."

Weight loss drugs 'linked to hair loss' – study

Related Articles

Weight loss drugs 'linked to hair loss' – study

Related Articles

(no title)

Scientists reverse brain aging, with a nasal spray

AI has torched the market for junior programmers

Al Vigier: Canada's AI strategy shouldn't include secret Palantir bills

The Anatomy of an AI-Native Org